{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:21:11Z","timestamp":1767136871733,"version":"build-2238731810"},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Initially approved for the fifth\u2010line or later therapeutic setting, the chimeric antigen receptor (CAR) T\u2010cell regimen ciltacabtagene autoleucel (cilta\u2010cel) was recently approved for second\u2010line (2L) treatment in relapsed\/refractory multiple myeloma (RRMM). Oncology practitioners use clinical trials to inform treatment, but real\u2010world impressions and impact on practice are lacking. We aimed to determine whether presenting CARTITUDE\u20104 clinical trial data would impact real\u2010world preferences\/perceptions around CAR T\u2010cell therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Recruiting from the Cardinal Health Oncology Provider Extended Network (OPEN), we surveyed hematologists\/oncologists to investigate fourth\u2010line (4L) preferences in a hypothetical patient with triple\u2010class\u2013refractory MM. We posed the same questions and answers before and after the trial presentation and compared pre\u2010\/post\u2010preferences toward cilta\u2010cel and sequencing relative to bispecific antibodies (BsAbs). Using the same methodology as described above, we also performed a secondary analysis comparing pre\u2010\/post\u2010perceptions on the use of CAR T\u2010cell therapy in earlier lines for patients with triple\u2010class\u2013refractory MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 50 respondents, decision\u2010making factors before the trial presentation included CAR T\u2010cell center availability (58%), comorbidities (52%), and center locations (34%). Additionally, 48% of 46 respondents chose 4L cilta\u2010cel. Among 47, 40% wanted more real\u2010world\/long\u2010term CAR T\u2010cell therapy outcomes in any line, 38% wanted more 2L data, and 34% favored 2L\/third\u2010line (3L) use. After the presentation, the preference for cilta\u2010cel doubled from 48% to 88% (\n                      <jats:italic>p\u00a0<\/jats:italic>\n                      &lt;\u00a00.001) among 50 respondents and rose from 34% to 55% (\n                      <jats:italic>p\u00a0<\/jats:italic>\n                      =\u00a00.001) for earlier\u2010line CAR T\u2010cell therapy among 49. Moreover, 55% of 49 respondents preferred CAR T\u2010cell therapy prior to BsAbs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>We have shown that making oncology practitioners aware of trials precipitated decision\u2010making factors and led to notable, significant shifts in future intended practice patterns. Being aware of trial data enables practitioners to make more informed decisions, tailor therapies to individual patients, and ultimately improve outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.1047","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T09:45:27Z","timestamp":1732527927000},"page":"1154-1164","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real\u2010world practitioner perceptions of CARTITUDE\u20104 results for patients with previously treated multiple myeloma"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5540-0755","authenticated-orcid":false,"given":"Alexandrina","family":"Balanean","sequence":"first","affiliation":[{"name":"Cardinal Health, LLC  Dublin Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Baird","sequence":"additional","affiliation":[{"name":"Cardinal Health, LLC  Dublin Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9930-4287","authenticated-orcid":false,"given":"Brooke","family":"Dulka","sequence":"additional","affiliation":[{"name":"Cardinal Health, LLC  Dublin Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Jennings\u2010Zhang","sequence":"additional","affiliation":[{"name":"Cardinal Health, LLC  Dublin Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-8918","authenticated-orcid":false,"given":"Robert N.","family":"Bone","sequence":"additional","affiliation":[{"name":"Cardinal Health, LLC  Dublin Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1711-849X","authenticated-orcid":false,"given":"Yolaine","family":"Jeune\u2010Smith","sequence":"additional","affiliation":[{"name":"Cardinal Health, LLC  Dublin Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-9994","authenticated-orcid":false,"given":"Bruce","family":"Feinberg","sequence":"additional","affiliation":[{"name":"Cardinal Health, LLC  Dublin Ohio USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0630-8458","authenticated-orcid":false,"given":"Muhamed","family":"Baljevic","sequence":"additional","affiliation":[{"name":"Department of Medicine Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02515"},{"key":"e_1_2_14_4_1","unstructured":"National Cancer Institute. Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ\u00ae)\u2013Health Professional Version.2024. Accessed June 12 2024.https:\/\/www.cancer.gov\/types\/myeloma\/hp\/myeloma\u2010treatment\u2010pdq#_38_toc"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0061"},{"key":"e_1_2_14_6_1","unstructured":"JaberN.FDA approves BCMA\u2010targeted CAR T\u2010cell therapy for multiple myeloma. National Cancer Institute.2021. Accessed June 12 2024.https:\/\/www.cancer.gov\/news\u2010events\/cancer\u2010currents\u2010blog\/2021\/fda\u2010ide\u2010cel\u2010car\u2010t\u2010multiple\u2010myeloma"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10237-3"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3153"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26486"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2024.02.001"},{"key":"e_1_2_14_11_1","unstructured":"United States Food and Drug Administration.ABECMA: highlights of prescribing information.2024."},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_14_13_1","unstructured":"United States Food and Drug Administration.Carvykti: highlights of prescribing information.2024."},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_2_14_16_1","unstructured":"JaberN.Carvykti approval marks second CAR T\u2010cell therapy for multiple myeloma. National Cancer Institute.2022. Accessed June 12 2024.https:\/\/www.cancer.gov\/news\u2010events\/cancer\u2010currents\u2010blog\/2022\/fda\u2010carvykti\u2010multiple\u2010myeloma"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991092"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA106"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163923"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e13571"},{"key":"e_1_2_14_22_1","unstructured":"Bruce FeinbergAJK BalaneanA SchulerT McAllisterL LiassouD GajraA et\u00a0al.Completeness of real\u2010world data in chimeric antigen receptor t\u2010cell therapy for relapsed\/refractory diffuse large B\u2010cell lymphoma in United States Community Oncology\/Hematology Sites. 2022. Paper presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting; May 15 2022."},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.521"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.5003"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.10026"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_389860"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0020"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125286"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10529-023-03461-0"},{"issue":"1","key":"e_1_2_14_30_1","first-page":"1","article-title":"Challenges for CAR\u2010T cell therapy in multiple myeloma: overcoming the tumor microenvironment","volume":"2","author":"Cui JAG","year":"2023","journal-title":"Hematol Oncol Discov"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01001-1"},{"key":"e_1_2_14_32_1","unstructured":"Sagar LonialM CostaL RodriguezC CatameroD.CAR\u2010T vs BCMA bispecifics: navigating myeloma treatment decisions. Cancer Network.2023."},{"key":"e_1_2_14_33_1","article-title":"When choosing between bispecifics and CAR T, the best therapy may be what is accessible","volume":"30","author":"Mary C","year":"2024","journal-title":"Evid\u2010Based Oncol"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/frtra.2023.1238535"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0501"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.876339"},{"key":"e_1_2_14_38_1","unstructured":"IQVIA Institute for Human Data Science.Hematologic Cancer Opportunities for Patient Equality (HOPE).2024. Accessed June 14 2024."}],"updated-by":[{"DOI":"10.1002\/jha2.70050","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000}}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.1047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T07:47:43Z","timestamp":1734335263000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.1047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/jha2.1047"],"URL":"https:\/\/doi.org\/10.1002\/jha2.1047","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"2024-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}